miR-122-3p targets UBE2I to regulate the immunosuppression of liver cancer and the intervention of Liujunzi formula
Copyright © 2024 Elsevier B.V. All rights reserved..
ETHNOPHARMACOLOGICAL RELEVANCE: Liujunzi formula has been used to treat liver cancer in China for many years, but its underlying mechanism remains unclear. We previously found that decreased expression of miR-122-3p was associated with liver cancer. In this study, we aimed to explore the target of miR-122-3p and the effect of the Liujunzi formula on miR-122-3p and its downstream events in liver cancer.
MATERIAL AND METHODS: Bioinformatics pinpointed potential targets of miR-122-3p. The actual target was confirmed by miRNA mimic/inhibitor transfections and a dual-luciferase reporter assay. RNA-seq looked at downstream genes impacted by this target. Flow cytometry checked for changes in T cell apoptosis levels after exposing them to liver cancer cells. Gene expression was measured by RT-qPCR, western blotting, and immunofluorescence staining.
RESULTS: Cell experiments found the Liujunzi extract (LJZ) upregulated miR-122-3p and in a dose-dependent manner. Bioinformatics analysis found UBE2I was a potential target of miR-122-3p, which was validated through experiments using miRNA mimics/inhibitors and a dual-luciferase reporter assay. RNA-seq data implicated the NF-κB pathway as being downstream of the miR-122-3p/UBE2I axis, further confirmed by forcing overexpression of UBE2I. Bioinformatic evidence suggested a link between UBE2I and T cell infiltration in liver cancer. Given that the NF-κB pathway drives PD-L1 expression, which can inhibit T cell infiltration, we investigated whether PD-L1 is a downstream effector of miR-122-3p/UBE2I. This was corroborated through mining public databases, UBE2I overexpression studies, and tumor-T cell co-culture assays. In addition, we also confirmed that LJZ downregulates UBE2I and NF-κB/PD-L1 pathways through miR-122-3p. LJZ also suppressed SUMOylation in liver cancer cells and protected PD-1+ T cells from apoptosis induced by co-culture with tumor cells. Strikingly, a miR-122-3p inhibitor abrogated LJZ's effects on UBE2I and PD-L1, and UBE2I overexpression rescued the LJZ-mediated effects on NF-κB and PD-L1.
CONCLUSIONS: miR-122-3p targets UBE2I, thereby suppressing the NF-κB signaling cascade and downregulating PD-L1 expression, which potentiates anti-tumor immune responses. LJZ bolsters anti-tumor immunity by modulating the miR-122-3p/UBE2I/NF-κB/PD-L1 axis in liver cancer cells.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2024 |
---|---|
Erschienen: |
2024 |
Enthalten in: |
Zur Gesamtaufnahme - volume:329 |
---|---|
Enthalten in: |
Journal of ethnopharmacology - 329(2024) vom: 01. Apr., Seite 118081 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Guo, Zhenhui [VerfasserIn] |
---|
Links: |
---|
Themen: |
Anti-tumor immunity |
---|
Anmerkungen: |
Date Revised 07.04.2024 published: Print-Electronic Citation Status Publisher |
---|
doi: |
10.1016/j.jep.2024.118081 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM370595769 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | NLM370595769 | ||
003 | DE-627 | ||
005 | 20240408232941.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240404s2024 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1016/j.jep.2024.118081 |2 doi | |
028 | 5 | 2 | |a pubmed24n1369.xml |
035 | |a (DE-627)NLM370595769 | ||
035 | |a (NLM)38570148 | ||
035 | |a (PII)S0378-8741(24)00380-5 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Guo, Zhenhui |e verfasserin |4 aut | |
245 | 1 | 0 | |a miR-122-3p targets UBE2I to regulate the immunosuppression of liver cancer and the intervention of Liujunzi formula |
264 | 1 | |c 2024 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 07.04.2024 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status Publisher | ||
520 | |a Copyright © 2024 Elsevier B.V. All rights reserved. | ||
520 | |a ETHNOPHARMACOLOGICAL RELEVANCE: Liujunzi formula has been used to treat liver cancer in China for many years, but its underlying mechanism remains unclear. We previously found that decreased expression of miR-122-3p was associated with liver cancer. In this study, we aimed to explore the target of miR-122-3p and the effect of the Liujunzi formula on miR-122-3p and its downstream events in liver cancer | ||
520 | |a MATERIAL AND METHODS: Bioinformatics pinpointed potential targets of miR-122-3p. The actual target was confirmed by miRNA mimic/inhibitor transfections and a dual-luciferase reporter assay. RNA-seq looked at downstream genes impacted by this target. Flow cytometry checked for changes in T cell apoptosis levels after exposing them to liver cancer cells. Gene expression was measured by RT-qPCR, western blotting, and immunofluorescence staining | ||
520 | |a RESULTS: Cell experiments found the Liujunzi extract (LJZ) upregulated miR-122-3p and in a dose-dependent manner. Bioinformatics analysis found UBE2I was a potential target of miR-122-3p, which was validated through experiments using miRNA mimics/inhibitors and a dual-luciferase reporter assay. RNA-seq data implicated the NF-κB pathway as being downstream of the miR-122-3p/UBE2I axis, further confirmed by forcing overexpression of UBE2I. Bioinformatic evidence suggested a link between UBE2I and T cell infiltration in liver cancer. Given that the NF-κB pathway drives PD-L1 expression, which can inhibit T cell infiltration, we investigated whether PD-L1 is a downstream effector of miR-122-3p/UBE2I. This was corroborated through mining public databases, UBE2I overexpression studies, and tumor-T cell co-culture assays. In addition, we also confirmed that LJZ downregulates UBE2I and NF-κB/PD-L1 pathways through miR-122-3p. LJZ also suppressed SUMOylation in liver cancer cells and protected PD-1+ T cells from apoptosis induced by co-culture with tumor cells. Strikingly, a miR-122-3p inhibitor abrogated LJZ's effects on UBE2I and PD-L1, and UBE2I overexpression rescued the LJZ-mediated effects on NF-κB and PD-L1 | ||
520 | |a CONCLUSIONS: miR-122-3p targets UBE2I, thereby suppressing the NF-κB signaling cascade and downregulating PD-L1 expression, which potentiates anti-tumor immune responses. LJZ bolsters anti-tumor immunity by modulating the miR-122-3p/UBE2I/NF-κB/PD-L1 axis in liver cancer cells | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Anti-tumor immunity | |
650 | 4 | |a Liujunzi formula | |
650 | 4 | |a Liver cancer | |
650 | 4 | |a PD-L1 | |
650 | 4 | |a UBE2I | |
650 | 4 | |a miR-122-3p | |
700 | 1 | |a Wang, Yiqi |e verfasserin |4 aut | |
700 | 1 | |a Qin, Wanting |e verfasserin |4 aut | |
700 | 1 | |a Heng, Yin |e verfasserin |4 aut | |
700 | 1 | |a Chen, Xi |e verfasserin |4 aut | |
700 | 1 | |a Liu, Na |e verfasserin |4 aut | |
700 | 1 | |a Li, Jinzhe |e verfasserin |4 aut | |
700 | 1 | |a Wu, Haitao |e verfasserin |4 aut | |
700 | 1 | |a Zhou, Ying |e verfasserin |4 aut | |
700 | 1 | |a Zhang, Ren |e verfasserin |4 aut | |
700 | 1 | |a Song, Shanshan |e verfasserin |4 aut | |
700 | 1 | |a Wu, Zheli |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of ethnopharmacology |d 1980 |g 329(2024) vom: 01. Apr., Seite 118081 |w (DE-627)NLM00095196X |x 1872-7573 |7 nnns |
773 | 1 | 8 | |g volume:329 |g year:2024 |g day:01 |g month:04 |g pages:118081 |
856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jep.2024.118081 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 329 |j 2024 |b 01 |c 04 |h 118081 |